SUMMARY
MHC class II molecules (MHC-II) present peptides to T helper cells to facilitate immune responses and are strongly linked to autoimmune diseases. To unravel processes controlling MHC-II antigen presentation, we performed a genome-wide flow cytometry-based RNAi screen detecting MHC-II expression and peptide loading followed by additional high-throughput assays. All data sets were integrated to answer two fundamental questions: what regulates tissuespecific MHC-II transcription, and what controls MHC-II transport in dendritic cells? MHC-II transcription was controlled by nine regulators acting in feedback networks with higher-order control by signaling pathways, including TGFb. MHC-II transport was controlled by the GTPase ARL14/ARF7, which recruits the motor myosin 1E via an effector protein ARF7EP. This complex controls movement of MHC-II vesicles along the actin cytoskeleton in human dendritic cells (DCs). These genome-wide systems analyses have thus identified factors and pathways controlling MHC-II transcription and transport, defining targets for manipulation of MHC-II antigen presentation in infection and autoimmunity.
INTRODUCTION
Major histocompatibility complex class II molecules (MHC-II) present peptides to CD4+ T cells that initiate and control immune responses. The expression of MHC-II is mostly restricted to professional antigen-presenting cells (APCs), such as B cells and dendritic cells (DCs), and is controlled by a transcriptional complex that includes the MHC-II transactivator CIITA (Reith et al., 2005) . Careful regulation of expression is needed to prevent uncontrolled immune responses. Various allelic forms of MHC-II are associated with autoimmune diseases (Chaplin and Kemp, 1988) . The successful presentation of peptides at the cell surface involves a series of subcellular events. In the ER, MHC-II associates with the invariant chain (Ii) that fills the peptide-binding groove and mediates transport to late endosomal compartments called MHC-II compartments (MIICs) (Neefjes et al., 1990; Roche and Cresswell, 1990) . There, Ii is degraded, leaving a fragment called CLIP in the peptide-binding groove of MHC-II (Riberdy et al., 1992) . In parallel, endocytosed antigens are degraded into peptides, which compete with CLIP for binding to MHC-II in a process catalyzed by the chaperone HLA-DM (DM) (Denzin et al., 1996; Sloan et al., 1995) in the intraluminal vesicles of the MIIC (Zwart et al., 2005) . Ultimately, MHC-II-containing vesicles and tubules fuse with the plasma membrane (Boes et al., 2002; Chow et al., 2002; Wubbolts et al., 1996) to present the peptide-loaded MHC-II to CD4 + T cells.
Various factors controlling MHC-II expression have been identified, such as cytokines that can inhibit (IL-10) (Koppelman et al., 1997) or upregulate (interferon-g) (Steimle et al., 1994) MHC-II expression. Certain activation signals, such as TLR signaling, can also upregulate its expression in B cells and DCs (Blander and Medzhitov, 2006) . IL-10 signaling may upregulate MARCH I, which ubiquitinates and shortens MHC-II half-life (Thibodeau et al., 2008) . Other factors such as pH (Ziegler and Unanue, 1982) , kinases (Anderson and Roche, 1998) , and cholesterol (Kuipers et al., 2005) affect MHC-II expression and antigen presentation.
As a first step toward a systems understanding of MHC-II antigen presentation, we performed a multidimensional RNAi screen in which we investigated cell surface expression of MHC-II, as well as peptide loading, transcriptional control, and intracellular distribution in an integrated manner. Combining these phenotypic analyses yielded factors and pathways controlling MHC-II transcription and transport in DCs and defined targets for manipulation of MHC-II antigen presentation in infection and autoimmunity.
RESULTS

Genome-wide RNAi Screen Identifies 276 Candidate
Genes Affecting MHC-II Expression and Peptide Loading MHC-II is selectively expressed by APCs. To identify proteins and networks involved in MHC-II expression and peptide loading, we selected the human melanoma cell line MelJuSo, which expresses peptide-loaded MHC-II and all components required for MHC-II antigen presentation (Wubbolts et al., 1996) . Whereas MelJuSo is not an immune cell type, it does express many immune-specific genes and proteins controlling MHC-II transport similar to DCs. APCs express Toll-like receptors (TLRs) recognizing double-stranded siRNA, resulting in activation signals that might increase MHC-II expression (Agrawal and Kandimalla, 2004; Reynolds et al., 2006) . MelJuSo lacks these TLRs and in addition exhibits transfection efficiencies greater than 95%, as well as stable MHC-II expression and peptide loading capacity (data not shown). These features, which are essential for reliable RNAi screens, are not shared by any primary APC tested.
To visualize the effects of gene knockdown on MHC-II expression and peptide loading, we used two monoclonal antibodies ( Figure 1A ): Cy5-conjugated CerCLIP, which recognizes human Figure 1 . A Genome-wide Flow Cytometry-Based RNAi Screen (A) MelJuSo transfected with siRNA were analyzed for surface expression of peptide-versus CLIP-loaded MHC-II by high-throughput flow cytometry using monoclonal antibodies (L243-Cy3 and CerCLIP-Cy5). The graphs show representative Z scores of siRNAs without effect (jzj < 3; black line), untreated cells (green), HLA-DM-silencing (orange), and candidates after normalization (jzj > 3; blue). Inlay in the CerCLIP plot shows the Z 0 factor for the analysis of the kinase sublibrary, representing the detection window between negative (blue) and positive controls (red).
(B) Scheme showing the different confirmation steps in the screening procedure resulting in 276 candidate genes influencing MHC-II expression and peptide loading. Indicated is the distribution of four phenotypes detected by flow cytometry. See also Table S1 and Table S2. MHC-II loaded with the residual Ii-derived CLIP fragment, and Cy3-conjugated L243, which recognizes peptide-loaded MHC-II (called HLA-DR). CLIP-loaded MHC-II reflects an inefficiency of the loading of antigenic peptide on the mature receptor (Denzin et al., 1994) , whereas L243 detects correctly loaded MHC-II on the plasma membrane (Lampson and Levy, 1980) . MelJuSo cells were transfected with pools of siRNAs (four duplexes per target gene) in 96-well format targeting 21,245 human genes in total. Three days posttransfection, cells were analyzed by flow cytometry to determine peptide loading as well as expression levels of MHC-II. The primary screen (performed in triplicate) achieved an excellent ''screening window'' (difference of negative and positive control) defined by the Z 0 factor (Zhang et al., 1999) . All parts yielded Z 0 > 0.5 ( Figure 1A ; Z 0 for the kinase sublibrary). Results were Z score normalized. Genes whose silencing resulted in a change of L243 or CerCLIP staining by jzj > 3 (p < 0.0027) were considered candidates for follow up. These genes were rescreened in triplicate, resulting in 789 candidate proteins with potential functions in controlling MHC-II expression and peptide loading ( Figure 1B) .
To determine which of the 789 candidates identified in the screen were expressed in APCs, we performed microarray gene expression analysis on human primary monocytes, monocyte-derived (activated and immature) DCs, and naive or CD40L-activated B cells (Table S1 available online). Of the candidate genes identified in MelJuSo cells, 532 genes were expressed in one or more human primary APC type. Correcting for off-target effects (see Experimental Procedures) resulted in 276 confirmed candidates (Table S2) . These candidates could be divided into four groups based on differential staining with L243 or CerCLIP, which allowed the distinction between effects on MHC-II expression versus effects on peptide loading, respectively. Most candidate proteins identified in the screen appeared to affect MHC-II surface expression; only 45 genes specifically affected peptide loading (CLIP up; Figure 1B ).
Candidate Proteins Include Known MHC-II Pathway Components and Proteins Associated with Autoimmunity
To annotate the function of the 276 identified genes, we used database tools to determine tissue distribution, potential function, association with autoimmune diseases, and established function in the MHC-II antigen presentation pathway. First, as a validation of our method, we interrogated the data set for proteins already known to be involved in MHC-II antigen presentation. Thirteen candidates have been reported in literature to control MHC-II antigen presentation (Figure 2A , green/yellow proteins), including the MHC-II transcriptional regulator CIITA, the HLA-DRA and DRB chains, DM, and the IL-10 receptor. Another set of 13 proteins might indirectly correlate to the pathway through inhibitors or as targets of pathogenic immune regulators ( Figure 2A , blue proteins). For example, FK506-binding protein 3 (FKBP3) may be the target of FK506 (Imai et al., 2007) . The target(s) for general kinase inhibitor Staurosporine (Anderson and Roche, 1998) can be included in the 28 serine/ threonine kinases that we identified in our screen. Also, the immunodeficiency virus (HIV) protein Tat has been postulated to control HIV-Tat interacting protein (HTATIP) (Kamine et al., 1996) (Figure 2A ), which we picked up in our screen as a regulator of MHC-II peptide loading. Hence, some 10% (26 of 276) of our primary screen candidates have already been implicated in controlling MHC-II expression and peptide loading. In our initial screen, however, we did not identify all factors that had been reported in literature to control MHC-II function. We thus retested these separately, which revealed that most of them yielded effects below our cut-off of jzj > 3 ( Figure S1 ). Second, to determine which candidate genes were selectively expressed in immune tissues, we interrogated a gene expression database of 79 human tissues (Wu et al., 2009 ) and compared expression levels of each candidate between immune and other tissues. The expression of CIITA is limited to antigen-presenting cells; therefore we used its expression as a standard for immune specificity ( Figure 2B ). Sixty-nine of the 276 candidates identified by the RNAi screen exhibited selective expression in immune tissues (Table S1 ).
Another interesting group in which some of our candidates could be placed was associated with autoimmunity. Genetic association studies have revealed that MHC-II is the strongest autoimmunity-associated factor (Chaplin and Kemp, 1988) , possibly triggering the immune response by presenting autoantigens. Comparing our candidates involved in MHC-II regulation with a database containing genes linked to autoimmune diseases (http://geneticassociationdb.nih.gov) showed that 8% (21 of 276) were associated with autoimmune diseases (Figure 2C ). This association, together with their immune tissuespecific expression pattern, makes some of them attractive therapeutic targets for manipulating MHC-II function.
A standard protocol in genome-wide screening is pathway analysis based on literature. We first subclustered candidates into four groups based on their flow cytometry parameters ( Figure 1B ) before functional annotation by Ingenuity Pathway Analysis (http://www.ingenuity.com; Figure 2D and Table S2 ). Many enzyme classes are found to be involved in MHC-II antigen presentation, but the majority of genes had no ascribed function. The four groups were then analyzed by Ingenuity Pathways Analysis and STRING (Snel et al., 2000) for established protein interactions and yielded several networks consisting of annotated proteins only ( Figure S2 ). Analysis of these networks revealed clusters of proteins already known to be involved in MHC-II antigen presentation. No novel clusters regulating MHC-II became apparent from this network analysis. As most proteins had unknown functions, these pathways only covered a small fraction of candidate proteins. Hence, network analysis using different database tools was unsatisfactory in terms of describing the systems biology of MHC-II antigen presentation.
Therefore, we aimed at placing candidates in functional networks following secondary high-throughput screens. We broke down MHC-II antigen presentation in three processes: (1) peptide loading, (2) transcriptional regulation, and (3) the general cell biology of MHC-II. The latter category consists of the assembly, intracellular transport, processing in the MIIC, and endo-and exocytosis. Factors affecting peptide loading were already identified by the antibody CerCLIP in the primary screen.
After genome-wide screening, we were able to confirm our strategy by identifying known members of the MHC-II pathway. Figure S1 . EE, early endosome; MIIC, MHC class II-containing compartment; Ii, invariant chain. (B) Gene expression ratios of the candidate genes in the primary human immune cells (1) used in our selection procedure ( Figure 1B ) and immune tissues (2) versus nonimmune tissues (3). Gray areas indicate absence of probes on the expression arrays. Expression levels of (2) and (3) See also Figure S2 and Table S1 and Table S2 .
Furthermore, we have highlighted interesting therapy targets displaying immune-tissue specific expression and association to autoimmune diseases. Secondary high-throughput assays are needed to decipher the candidates involved in the transcriptional regulation and general cell biology of MHC-II.
Nine Candidates Are Implicated in Transcriptional and Higher-Order Control of MHC-II Expression MHC-II mRNA expression is controlled by CIITA. To determine whether the 276 candidate genes identified in the earlier RNAi screen affected MHC-II transcription, we silenced the 276 candidates in MelJuSo cells and performed quantitative PCR for mRNA of MHC-II (HLA-DRA), CIITA, and Ii. To check whether the candidates from our screen controlled the entire MHC locus, MHC class I transcription (HLA-A/B/C) was assessed (Horton et al., 2004) . The silencing of nine candidate proteins affected transcription of one or several of the tested genes ( Figure 3A and Table S3 ). Silencing of three candidate genes (CIITA itself, RMND5B, and PLEKHA4) downregulated CIITA and HLA-DR mRNA levels: the protein RMND5B has an unknown function, and PLEKHA4 has so far only been described as a phosphoinositide-binding protein. The silencing of three other genes (KIAA1007 [CNOT1], CDCA3, and MAPK1) upregulated both CIITA and HLA-DR transcription. CNOT1 is part of a transcription regulatory complex called CCR4-NOT. This complex also contains another protein identified in our primary screen called CNOT2. MAPK1 is a key signaling intermediate in many well-studied pathways, and the function of CDCA3 is yet unknown. MAPK1 (and CIITA itself) were the only genes shown to affect the whole MHC-locus, as measured by MHC class I (MHC-I) expression.
Knockdown of unknown EFHD2 and HTATIP increased the expression levels of HLA-DR and Ii. Silencing of only one gene (IL27RA, the IL-27 receptor) affected MHC-I expression independently of CIITA. This probably represents a more locusspecific effect. IL-27RA has been implicated in Th1-type as well as innate immune responses. For a full description of the candidates that affect MHC-II transcription, see Table S3 .
These nine candidate genes, including CNOT2, can affect each others' expression as well as that of CIITA, HLA-DR, Ii, and MHC-I. To define potential interconnections, we performed a ''cross-correlative qPCR''. Each candidate was silenced, and the effect on expression of the other candidates was determined by qPCR ( Figure 3B ). Most siRNAs affected the expression of one or more other candidate genes, suggesting that they act in complex networks ( Figure 3C ). These networks can be defined as controlling the CIITA expression (network 1), the MHC locus (network 2), or the selective transcription of HLA-DR and Ii (group 3).
We performed literature analysis to define higher-order regulation of the transcriptional network controlling MHC-II expression. Seven of the candidates affecting MHC-II transcription have already been annotated to pathways. FLJ22318/RMND5B (human homolog of yeast required for meiotic muclear division 5B protein), on the other hand, is not functionally annotated, but an interaction with SMAD4 has been reported (Colland et al., 2004) . SMAD proteins transduce signals from the TGFb receptor to the nucleus to downregulate MHC-II expression (Dong et al., 2001) . To understand the role of this unknown factor, we tested whether RMND5B is involved in TGFb signaling. Following exposure to TGFb for 3 days, MHC-II was downregulated in MelJuSo. RMND5B silencing further downregulated MHC-II expression as detected by flow cytometry and qPCR ( Figures 3D and 3E ). RMND5B might thus act as an inhibitor of SMADs. SMAD4 translocates from cytosol to nucleus upon TGFb exposure (Shi and Massagué , 2003) , which was also observed for RMND5B in MelJuSo ( Figure 3F ). Although we failed to show a direct interaction with SMAD4, we placed RMND5B in a network controlled by TGFb signaling, which controls MHC-II expression.
We have defined a transcriptional network controlling MHC-II expression. Furthermore, we described a network of higherorder control based on proteins annotated in literature (Figure 3G ; for references, see Figure S3 ). These networks should, in principle, explain the immune tissue-selective expression of MHC-II. The data show that CIITA expression is controlled by a complex transcriptional feedback mechanism, which in turn is controlled by a series of general biological processes such as chromatin modification, the cell cycle, and a number of different signaling events, including those mediated by TGFb and RMND5B. The combined input of events presumably determines the tissue selectivity of MHC-II expression.
Analysis of Networks with Similar Intracellular MHC-II Distribution Phenotypes Selects Candidates for In-Depth Study
Nine candidate genes were shown to control the transcription of MHC-II. This implies that the other 268 candidates could affect the intracellular distribution of MHC-II. This we evaluated by microscopy. A clonal MelJuSo cell line expressing MHC-II-GFP and mCherry-GalT2 (a Golgi marker) was transfected with siRNAs for the candidates. The nuclei (Hoechst) and early endosomes (anti-EEA1) were stained to detect all relevant intracellular compartments of MHC-II ( Figure 4A and Figure S4A ). The resulting images were processed with CellProfiler software (Carpenter et al., 2006) , which resulted in more than 100 parameters describing the features of nuclei, endosomes, Golgi, and plasma membrane. Images were analyzed and scored using automated image analysis software (CPAnalyst2; see Extended Experimental Procedures for analysis parameters) (Jones et al., 2009) . Particular phenotypes could be characterized in this manner, e.g., enlarged MHC-II-positive vesicles, MHC-II redistribution to the plasma membrane, clustering or dispersion of early endosomes, and altered Golgi structure ( Figure 4B ). After several rounds of software training, the minimal number of parameters (out of the > 100) needed to distinguish the phenotypes was determined ( Figure S4B and Table S4 ). After Z score normalization, the siRNAs giving similar phenotypes were clustered ( Figure 4C ). Control siRNAs (positive and nonaffecting) were clustered in distinct groups, thereby validating our method.
To obtain an overview of our data, we built a network tree integrating information of all the different screens. The fill color of each gene shows the effect on MHC-II surface expression (L243, flow cytometry screen), whereas the color of the edge represents mRNA level changes going from immature (im)DCs to mature (m)DCs, as found by microarray. The size of the (Table S2 ) and qPCR.
(B) Upon silencing the genes defined under (A), the effect on the expression levels of the nine genes and the MHC-II factors was determined by qPCR. Confirmed effects of at least two experiments are shown (green, downregulation; red, upregulation; gray, no effect). See also Figure S3 and Table S3 . y node correlates to an increase in the relative amount of MHC-II at the surface, an mDC-like phenotype (Cella et al., 1997; Pierre et al., 1997) . This feature was deduced from the microscopic analysis (Table S4) . Candidate genes grouped in the same branch of the diagram, due to similar phenotypes generated, were postulated to act in the same functional pathways. We set an arbitrary threshold to distinguish four highly homologous clusters in our tree diagram (distance to root R 153.6, genes per cluster R 15, indicated by blue lines in Figure 4C ; see also Figure S5 ). These clusters also included unknown proteins that might be functionally connected to known proteins present in the same cluster. These connections may be better understood after in-depth experimental validation.
To understand the function of the identified clusters, we determined the enrichment of Gene Ontology (GO) terms. As expected, all candidates identified by the screens were enriched for the GO cellular component term ''MHC-II protein complex'' (p = 0.0028815; Table S5 ). For a more extensive analysis, we applied the integrated functional gene network program Humannet v. 1 (Kim et al., 2008) , which combines information from several expression and protein-protein interaction databases. We first measured the degree of connectivity between our candidates by the area under the receiver operating characteristic (ROC) curve (AUC) ( Figure S6 ). The AUC of 0.6175 indicates that many connected genes (neighbors) also genuinely interact. Neighbors with a log-likelihood score R 1 according to Humannet and a jzj R 1.645 (p < 0.1) in our original flow cytometry screen were also included in this analysis (Table S6) . These increased the number of proteins involved in the same functional pathway. Subsequent GO analysis of the expanded groups indicated that clusters 2 and 4 ( Figure 4C ) were enriched for ''MHC-II protein complex'' (Table S5 ). When we combined this information with the microscopy phenotypes, we noted that the genes in cluster 4 did not affect MHC-II distribution, whereas those in cluster 2 showed MHC-II redistribution to the cell surface that resembles an mDC phenotype ( Figure 6A ). Cluster 2 has two areas where the genes cohered ( Figure 5A) ; one was enriched for GO terms like ''MHC-II protein complex'' ( Figure 5B ) and another for ''cytosolic ribosome'' terms (cells with reduced intracellular MHC-II [data not shown]).
The definition of clusters combined with functional annotation predicts connections between candidates within a network. This allows the addition of genes to these networks, which were not originally identified in our siRNA screen (for reasons of functional redundancy, effect below cut-off, etc.). Our integrative bioinformatic approach enables us to select candidates for further biochemical studies based on their predicted functional relationships and effects observed in our various screens.
Six Proteins Involved in MHC-II Redistribution in Maturing DCs
To test whether our networks indeed predict processes that are essential in the immune system, we studied MHC-II distribution in DCs. DCs exposed to maturation signals redistribute MHC-II molecules and various activation markers from CD63-positive vesicles to the plasma membrane, enhancing their surface expression. This is an essential step in the acceleration of immune responses (Cella et al., 1997; Pierre et al., 1997) (Figure 6A) . MHC-II distribution is visualized in a colocalization pixel plot of CD63 versus MHC-II ( Figure 6A, right) . To select candidates that are potentially involved in the control of MHC-II redistribution in DCs, we used the following arguments. First, the genes should upregulate MHC-II expression at the cell surface (as in mDCs). Second, if upregulation is caused by silencing, the candidate should be downregulated in the microarray analyses from imDC to mDC. Lastly, silencing of genes should induce MHC-II transport to the plasma membrane as determined by microscopy ( Figure 4C , Table S1, and Table S2 ). Nine unrelated candidates fulfilled all criteria, and we tested whether silencing these genes in imDCs could mimic the reduction in expression following activation and therefore alter the distribution of MHC-II ( Figure 6B ).
Four individual shRNA sequences per gene were introduced into primary human monocytes before differentiation into imDCs, detected by decreased monocyte marker CD14 and increased DC marker DC-SIGN expression. Typical activation markers for mDCs remained absent ( Figure 6C ). Seven out of nine selected candidates increased CerCLIP and/or MHC-II expression in imDCs 6 days after shRNA transduction of monocytes ( Figure 6D and Figure S7A ), similar to the effects in the primary screen. As controls, we silenced CIITA and DM, obtaining the anticipated effects on L243 and CerCLIP levels, respectively. Gene silencing was confirmed by qPCR for representative shRNA constructs ( Figure 6E) .
Next, the effect of silencing the nine candidates on the distribution of MHC-II in imDCs was studied by confocal microscopy. A gallery of representative images is shown in Figure S7B . Six candidates showed a significant redistribution of MHC-II from CD63-positive compartments to the plasma membrane, which mimics the distribution of MHC-II in mDCs ( Figure 6F and Figure S7C) . Silencing of undefined proteins FLJ20249 (GPATCH4) and FLJ22595 (the small GTPase ARL14/ARF7), as well as the A) MelJuSo stably expressing MHC-II (HLA-DRB1-GFP, green) and a Golgi marker (mCherry-GalT2, red) were transfected with siRNA targeting the 276 candidate genes and stained for early endosomes (EEA1) in blue and nucleus (Hoechst, not shown). (B) Confocal images of all silenced genes were analyzed using CellProfiler and CPAnalyst 2. In the process of ''supervised machine learning,'' siRNAs resulting in similar phenotypes were manually grouped into several bins for the different fluorescent channels. Shown are panels with representative images used for computer instruction. The minimal number of descriptive parameters for each group was determined. (C) Organic view of clustered genes based on phenotype determined by quantitative microscopy analysis. The color of the nodes indicates the Z score for the L243 staining (red, upregulation; green, downregulation). The nodes' border color indicates the change in mRNA levels upon DC maturation (red, higher; green, lower expression). Node size represents a measure of mDC phenotype. A larger node is correlated to higher cell membrane MHC-II levels related to intracellular vesicles. Names in large font indicate selected candidates for further testing in DCs. Example images of genes from selected clusters are shown. Scale bar, 25 mm. See also Figure S4 , Figure S5 , Table S4 . See also Figure S6 , Table S5, and Table S6. transcription factor MAFA, strongly affected localization. Redistribution of MHC-II was also observed for coat protein complex II protein SEC13L1 (SEC13), Golgi protein GOLPH3-like GPP34R, and PDCD1LG1 (CD274), a molecule that is widely expressed on immune cells involved in the regulation of T cell responses. Our strategy identified proteins controlling MHC-II transport in imDC that would not have been selected without an unbiased approach. Silencing these genes generated imDCs with an mDC-like MHC-II distribution. These proteins control most of the specific immune responses and may be targets for manipulation aimed at controlling these.
A Pathway of the GTPase ARL14/ARF7 and Actin-Based Motor Myosin 1E Controls MHC-II Transport in DC We defined various proteins controlling MHC-II transport in DCs. One of these, the GTPase ARL14/ARF7, was detected on MHC-II vesicles in imDCs ( Figure 7A ) and selected as a starting point for building a pathway aimed at understanding the molecular basis of MHC-II transport in DCs. Guanine exchange factors (GEFs) activating ARF GTPases are specified by SEC7 domains (Casanova, 2007) . We scanned the data set of the primary screen (Figure 1) for proteins containing SEC7 domains that upregulated MHC-II expression, similar to ARL14/ARF7. Two candidate GEFs were identified. Their SEC7 domains were expressed as MBP-tagged proteins for in vitro GTP loading assays of GST-ARL14/ARF7 and GST-ARF6 as control. Only PSD4/EFA6B/ TIC (selectively expressed in the immune system, Z = 2.22 in RNAi screen) promoted GTP loading of ARF6, as described (Derrien et al., 2002) , and ARL14/ARF7 ( Figure 7B ). The PH domain of PSD4 was produced as GST-fusion protein and was used in a lipid-binding assay that indicated specificity for various PIP2 species ( Figure 7C ). The candidates for controlling MHC-II transport in DC ( Figure 6B ) also included a regulatory subunit of PI3K (PIK3R2) (Deane and Fruman, 2004) and PIP5K1A, which can generate PIP2. Overexpressed GFP-PIP5K1A localized to the plasma membrane and partly colocalized with intracellular MHC-II and ARL14/ARF7-mCherry vesicles in MelJuSo cells ( Figure 7D ) and phagosomes (Mao et al., 2009) . Collectively, this reveals part of a pathway where PIP5K1A and PIK3R2 create PIPs that are required for recruitment or activation of the GEF PSD4, which activates ARL14/ARF7.
GTPases require effectors to transmit function. We performed yeast two-hybrid with ARL14/ARF7 as bait to identify C11ORF46 (now called ARF7 effector protein, or ARF7EP) (Table S7 ). This 29 kDa protein does not have any detectable domains and is selectively expressed in the immune system. The interaction was confirmed by isolating ARL14/ARF7 with ARF7EP from lysates of MelJuSo expressing HA-ARF7EP and RFP-ARL14/ ARF7 ( Figure 7E ). Immunostaining of MelJuSo cells expressing both proteins confirmed colocalization of ARL14/ARF7 and ARF7EP ( Figure 7F ).
Because ARF7EP does not provide any structural information that connects it to a biological pathway, we performed pull-down experiments with GST or GST-ARF7EP in cytosolic extracts of human PBMCs. Proteins found in the GST-ARF7EP isolate were identified by mass spectrometry as B-actin and actinbased motor protein myosin 1E (MYO1E). Pull-down experiments from HEK293T extracts showed specific recovery of GFP-tagged MYO1E by GST-tagged ARF7EP ( Figure 7G ). MYO1E is a single-headed actin-based motor highly expressed in the immune system. ARL14/ARF7 may connect to the actin network via ARF7EP-MYO1E to control export of MHC-II. To test this connection, human imDC were stained with anti-actin and anti-ARL14/ARF7 antibodies ( Figure 7H ), revealing ARL14/ ARF7 containing vesicles aligning with actin cables. The interaction between ARF7EP and MYO1E was further confirmed by immune precipitation from extracts of human PBMC ( Figure 7I) .
Various assays were integrated with the results of the RNAi screen to place proteins in one immune-specific pathway of actin-based control of MHC-II transport in imDC ( Figure 7J ). Manipulation of this pathway in imDCs to induce the characteristic MHC-II transport from intracellular stores to the plasma membrane could be the result of inactivation of the ARF7GEF PSD4 by changed behavior of PI3 and PI5 kinases. How these events are controlled in DCs during activation is unknown. By extensive data set integration, we defined a pathway controlling one of the most essential steps in immune cell activation: the redistribution of MHC-II to the plasma membrane in DCs after maturation.
DISCUSSION
We describe here the genome-wide analysis of an essential process in the immune system: antigen presentation by MHC-II. We identify 276 candidates with only 10% described thus far in the MHC-II pathway. Twenty-one candidates are linked to autoimmune diseases. As in our siRNA experiments, these genes may cause aberrant MHC-II expression in patients, which requires further experimental validation before consideration for therapeutic manipulation.
We have developed various methods to place the candidate genes in the systems of transcriptional and cell biological control of MHC-II antigen presentation. By flow cytometry, we selected 45 genes affecting peptide loading only, including HLA-DM and components of the ESCRT machinery that are involved in multivesicular body formation. A limited set of genes could be placed in networks by computer-based pathway analysis, unlike the majority of genes, which have an unknown function. This represents an enigma in high-throughput screening yielding large data sets and often results in preselecting one gene for in-depth analysis with limited new understanding of biology.
There are two important unelucidated processes in MHC-II antigen presentation, which we addressed in our study in detail: the control of tissue-specific expression of MHC-II and the regulation of MHC-II distribution in DCs. MHC-II expression is controlled by CIITA. How CIITA, in turn, is regulated is unclear. We discovered nine transcriptional regulators of MHC-II expression and performed cross-correlative qPCR to determine their interrelationships and their effects on CIITA expression. Five of these regulate the expression levels of CIITA in a complex feedback loop involving the (yeast meiosis) factor RMND5B and MAPK1 that phosphorylates and influences CIITA activity (Voong et al., 2008) . The remaining factors control MHC-II expression without affecting CIITA levels. This includes the HIV Tat-interacting . By combining experimental and literature data, we show that the activities of extracellular signaling, the cell cycle, and chromatin modifications control the transcriptional network for immune tissue-restricted MHC-II expression. Of note, pathogens also manipulate these pathways; HIV targets HTATIP, and L. monocytogenes targets SMAD4 (Kamine et al., 1996; Ribet et al., 2010) . Tissue-selective expression of MHC-II is thus orchestrated by a series of unrelated input signals. The details of how these cooperate to induce proper MHC-II expression remain unclear.
To identify proteins controlling MHC-II distribution, we silenced all candidates, and the effect on MHC-II distribution was visualized by microscopy. Candidate genes inducing a similar phenotype are expected to participate in one network, as illustrated in yeast screens that identified the ESCRT machinery (Teis et al., 2008) . We integrated our phenotypic clusters with databases like Humannet v. 1 to expand our networks and annotated these using GO analyses. Half of the genes in these clusters were predicted to control MHC-II trafficking but will require further experiments to validate their place in networks.
To select candidates involved in MHC-II redistribution in DCs, expression and functional RNAi data sets were combined to define six proteins controlling MHC-II transport. Silencing these resulted in imDCs with an mDC-like MHC-II distribution. These six candidates could act in one or parallel pathways.
One candidate, ARL14/ARF7, is a GTPase that is selectively expressed in immune cells. To build a pathway, we first localized ARL14/ARF7 on MHC-II compartments in imDC. Using domain predictions and in vitro assays, we defined the GEF for ARL14/ ARF7 as PSD4. PSD4 contains a PH domain with specificity for various PIP2 species, which may result from activities of two other proteins proposed to control MHC-II distribution in DCs: PIK3R2 and PIP5K1A. Whereas PI(3,5)P2 locates to late endosomes (Vicinanza et al., 2008) , the PH domain of PSD4 has a broader specificity and can therefore not induce selective targeting of PSD4 to late endosomes. The 60 kDa N-terminal domain of PSD4 may induce targeting to endosomal vesicles (Derrien et al., 2002) . When detecting PIP2, the PH domain of PSD4 might position the preceding SEC7 domain correctly for supporting GTP loading of ARL14/ARF7. To further expand the network, an interaction of the ARL14/ARF7 effector ARF7EP with the actin-based motor MYO1E was defined. This pathway connects general signaling events to actin-based transport control of MHC-II compartments in DCs.
Whereas PIK3R2 and PIP5K1A upstream are broadly expressed proteins, the other proteins in this pathway are more immune system selective. Of note, another candidate for controlling MHC-II distribution in DCs, PDCD1LG1 (CD274, PD-L1), activates PI3K via its receptor PD-1. PD-1 delivers inhibitory signals regulating T cell activation and tolerance. Little is known about PD-L1 signaling (Keir et al., 2008) , and this signaling may be irrelevant in mDC (Breton et al., 2009) . Tissue-selective control of actin-based transport by GTPases has been shown before for melanosomes where GTPase RAB27a binds MYO5A via its effector Melanophylin (Seabra and Coudrier, 2004) . MYO1E may be involved in granule secretion (Schietroma et al., 2007) as well as endocytosis by coupling to dynamin (Krendel et al., 2007) . MYO1E may have multiple functions in actin-based processes, depending on recruitment to specific locations. We define ARL14/ARF7-ARF7EP as a MYO1E receptor on MHC-II compartments for actin-based transport control. How the previously observed interaction between another actin-based motor MYH9 and MHC-II-associated Ii contributes to this process is unclear (Vascotto et al., 2007) .
The four remaining proteins controlling MHC-II transport in imDC could not be placed in this pathway: MAFA is a transcription factor for insulin in pancreatic b cells (Olbrot et al., 2002) . Our microarray data do not show any insulin production in DCs because the transcription cofactors Pdx-1 and NeuroD1 (Cerf, 2006) are not expressed. SEC13L1 (SEC13) is a COPII protein controlling transport between ER and Golgi (Tang et al., 1997) , which is a nonimmune-specific process in cells. GOLPH3L might have a similar function in the Golgi as GOLPH3 (Dippold et al., 2009) . The function of the fourth protein, GPATCH4, is unknown. It remains to be elucidated whether and how GPATCH4 could manipulate MHC-II antigen presentation.
We describe here a genome-wide analysis of molecules acting on a central controller in the immune system: MHC-II. After a first candidate selection by flow cytometry, we applied two additional high-throughput techniques and integrated the data with expression and protein interaction databases, cross-correlative qPCR, yeast two-hybrid, and proteomics. We defined Figure 6 . MHC-II Redistribution in imDCs (A and F) Immature (imDCs) and maturated (mDCs) DCs (A) or manipulated imDCs (F) were stained for MHC-II (green), CD63 (blue), actin (red, phalloidin), and nucleus (white, Hoechst) and were analyzed by confocal microscopy. Shown is the merge and the colocalization plot per pixel for CD63 versus MHC-II (right) with the normalized correlation coefficient indicated. Scale bar, 10 mm. (B) Selected candidate genes with primary screen phenotype (Table S2) a transcriptional network for MHC-II and CIITA and a cell biological pathway placing ARL14/ARF7, its effector ARF7EP, and MYO1E in control of actin-based MHC-II transport in DCs. This study identifies new targets and pathways for chemical and biological manipulation of MHC-II expression in various diseases, including autoimmunity.
EXPERIMENTAL PROCEDURES
siRNA Transfection, Flow Cytometry, and Microarray Gene silencing was performed in the human melanoma cell line (MelJuSo) using DharmaFECT transfection reagent #1 and 50 nM siRNA (Human siGenome SMARTpool library, Dharmacon). Three days posttransfection, cells were analyzed by flow cytometry (BD FACSArray) using L243-Cy3 (Lampson and Levy, 1980) and CerCLIP-Cy5 (Denzin et al., 1994) monoclonal antibodies. The data were normalized (cellHTS, Bioconductor) and transformed into Z scores (Boutros et al., 2006) . Expression levels of genes with jzj > 3 were determined by microarray analysis (Illumina) in primary human monocytes, DCs, and B cells, isolated and differentiated as previously described (Souwer et al., 2009; Ten Brinke et al., 2007) . Mature DCs were generated by culturing for 2 days in the presence of 2.5 mg/ml LPS (Invivogen) and 1000 U/ml IFNg (Immukine, Boehringer Ingelheim). For statistical analysis, p values were determined using the Student's t test.
Quantitative RT-PCR Messenger RNA was extracted (mRNA Capture Kit) and reverse transcribed into cDNA (Transcriptor High Fidelity cDNA Synthesis Kit). The quantitative RT-PCR was performed using LightCycler 480 SYBR Green 1 Master on the LightCycler 480 Detection System (all Roche). Quantification was performed using the comparative C T method (DDC T ). Primer sequences are available upon request.
Confocal Microscopy
Distribution of MHC-II, early endosomes, and Golgi was visualized by confocal microscopy (Leica AOBS microscope) using MelJuSo stably expressing HLA-DRB1-GFP, mCherry-GalT2 and was stained with anti-EEA1 (BD transduction laboratories) and Hoechst (Invitrogen). DCs were stained using Hoechst, Phalloidin-Alexa568 (Molecular Probes), anti-ARL14 2C8 (BioConnect), anti-CD63 (NKI-C3), and anti-HLA-DR (Neefjes et al., 1990) . Images were analyzed using CellProfiler 1.0.5811 (Carpenter et al., 2006) . CPAnalyst 2 was used to determine the minimal set of parameters needed to describe the relevant phenotypes (Jones et al., 2009 ). The ''Measure Correlation'' module of CellProfiler was used to determine the correlation between CD63 and MHC-II. MelJuSo cells were cultured with 3 ng/ml TGFb for 3 days. Cells were stained with anti-SMAD4 (Santa Cruz) and anti-RMND5B (Abcam) antibodies. Open and proprietary software was used for pathway analysis as extensively described in the Extended Experimental Procedures.
DC Manipulation
Human primary monocytes were transduced with lentiviral particles in the presence of 4 mg/ml polybrene (Millipore) at a MOI of 2. Viruses were produced by 293T cells transfected with packaging (pRSVrev, pHCMV-G VSV-G, pMDLg/pRRE) and pLKO.1shRNA constructs (Open Biosystems, Thermo Scientific) using Fugene 6 (Roche). Monocytes were subsequently cultured for 6 days in the presence of 800 U/ml IL-4 and 1000 U/ml GM-CSF (Cellgenix) to generate imDCs. DC cell surface marker levels were determined by flow cytometry after staining with the following mouse anti-human antibodies: FITC CD14, APC DC-SIGN, PE HLA-DR (L243), FITC CD83, APC CD40, PE CD80, and APC CD86 (all from BD).
Pathway-Building Techniques
Yeast two-hybrid was performed at DKFZ (Heidelberg) with ARL14-Q68L without myristoylation site cloned in pGBT9. ARF7EP was cloned in a bacterial expression vector as a GST-chimera and purified. Recombinant GST-ARF7EP and GST as a control were used to fish for endogenous MYO1E from cytosolic extracts of human PBMCs, and bound fractions were analyzed by mass spectrometry. Biochemical GEF assays were performed with purified MBP-tagged SEC7 domains from CYTH1 and PSD4 and GST-purified ARL14 or ARF6 using a 32 P-GTP. The PH domain of PSD4 was isolated as a GST-PHPH protein from 293T cells and was used to probe phospholipid membranes (tebu-bio). For antibodies used to immunoprecipitate, see Extended Experimental Procedures.
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